# Generate Biomedicines IPO (GENB): price, date and first-day trading

> Generate Biomedicines (GENB) priced its IPO at $16.00 a share and has traded on Nasdaq since Feb 27, 2026.

Canonical: https://massive.com/quote/genb/ipo
Data as of: 2026-11-19T11:38:09.951Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## GENB price

| Figure | Value |
| --- | --- |
| Price | $10.52 |
| Change from the IPO price | -34.25% |
| Change today | +6.91% |

## How GENB did against the market

GENB against the market, from its first trade at 12:50 ET to the last trade of the session.

| Measure | Value |
| --- | --- |
| GENB from its first trade | -13.73% |
| Against the market (QQQ) | -14.0 pts |

## The IPO scoreboard

GENB against other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.

| IPO | Raised | First trade | Day 1 close | Day 5 | Day 30 |
| --- | --- | --- | --- | --- | --- |
| Generate Biomedicines | $400M | -6.25% | -19.13% | -22.12% | -28.56% |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |

## The offering

| Term | Value |
| --- | --- |
| Expected price range | $15 to $17 |
| IPO price | $16.00 |
| Shares offered | 25M |
| Money raised | $400M |
| Listing date | Feb 27, 2026 |
| Exchange | Nasdaq |
| Security | Ordinary Shares |

## Where GENB ranks

The company's market cap against the largest US-listed companies.

| Company | Market cap |
| --- | --- |
| AAPL | $5.12T |
| MSFT | $3.77T |
| NVDA | $3.65T |
| GOOGL | $3.47T |
| AMZN | $2.9T |
| TSM | $1.88T |
| AVGO | $1.69T |
| META | $1.58T |
| TSLA | $1.52T |
| BRK.B | $1.22T |
| GENB | $1.34B |

## Insider buying and selling after the IPO

From Feb 27, 2026 to Nov 19, 2026, one GENB insider reported open-market sales of $200.7K across 2 filings; one chief executive officer bought $240.0K.

- Michael Nally, Chief Executive Officer: bought $240.0K, filed Mar 6, 2026
- Frances Arnold, Director: sold $184.7K, filed Nov 4, 2026
- Frances Arnold, Director: sold $16.0K, filed Sep 3, 2026

Sales made in the offering itself are left out.

[Who traded and when](https://massive.com/quote/genb/insider-trading.md)

## GENB news

- [2027 Could Finally Be the Year Cancer Is on the Ropes!](https://www.globenewswire.com/news-release/2026/10/30/3391989/0/en/2027-could-finally-be-the-year-cancer-is-on-the-ropes.html) · GlobeNewswire Inc. · Oct 29, 2026
- [Pharmaceutical Market Research: Global Industry to Reach USD 3.22 Trillion by 2035 as Biologics, AI-Driven Drug Discovery, and Manufacturing Investments Reshape Competition](https://www.globenewswire.com/news-release/2026/10/16/3382652/0/en/pharmaceutical-market-research-global-industry-to-reach-usd-3-22-trillion-by-2035-as-biologics-ai-driven-drug-discovery-and-manufacturing-investments-reshape-competition.html) · GlobeNewswire Inc. · Oct 16, 2026
- [Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday](https://www.fool.com/investing/2026/07/07/cathie-wood-goes-bargain-hunting-3-stocks-she-just/?source=iedfolrf0000001) · The Motley Fool · Jul 7, 2026
- [Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market](https://www.fool.com/investing/2026/06/27/nvidia-owns-under-radar-stock-trillion-market-genb/?source=iedfolrf0000001) · The Motley Fool · Jun 27, 2026
- [A Deep Dive Into Nvidia’s Latest Portfolio Moves](https://www.investing.com/analysis/a-deep-dive-into-nvidias-latest-portfolio-moves-200680639) · Investing.com · May 20, 2026
- [Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment \| DelveInsight \| DelveInsight](https://www.globenewswire.com/news-release/2026/04/07/3269524/0/en/Severe-Asthma-Clinical-Trial-Pipeline-Appears-Robust-With-30-Key-Pharma-Companies-Actively-Working-in-the-Therapeutics-Segment-DelveInsight-DelveInsight.html) · GlobeNewswire Inc. · Apr 7, 2026

## Filings and the company

Material events that Generate Biomedicines has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · Quarterly earnings ([filing](https://www.sec.gov/Archives/edgar/data/2100782/0001193125-26-456921.txt))
- Aug 26, 2026 · Clinical trial results ([filing](https://www.sec.gov/Archives/edgar/data/2100782/0001193125-26-365556.txt))
- Mar 2, 2026 · Charter amendment ([filing](https://www.sec.gov/Archives/edgar/data/2100782/0001193125-26-085780.txt))

## FAQ

### What was the Generate Biomedicines IPO price?

$16.00 a share.

### When did Generate Biomedicines go public?

Generate Biomedicines listed on Nasdaq on Feb 27, 2026 under the ticker GENB.

### How much did the Generate Biomedicines IPO raise?

$400M, before any underwriters' option.

### How did Generate Biomedicines open on its first day?

GENB first traded at $15.00, -6.25% from the IPO price of $16.00.

### How did GENB close on its first day?

Its last regular-session trade was $12.94, -19.13% from the IPO price of $16.00.

### What was the GENB first-day trading range?

$11.44 to $15.32 in the regular session.

### How many GENB shares traded on the first day?

5.82M shares in the regular session.

### How many shares did Generate Biomedicines sell in its IPO?

25M shares.

### How did GENB do against the market on its first day?

GENB fell 13.7% from its first trade to the last trade of the session. That is 14.0 points worse than the market (QQQ, the Nasdaq-100 ETF).

### What exchange is GENB listed on?

Generate Biomedicines lists on Nasdaq under the ticker GENB.

## Live data

The IPO record and the price come from the Massive API.

- `GET https://api.massive.com/vX/reference/ipos?ticker=GENB`
- `GET https://api.massive.com/v3/snapshot?ticker.any_of=GENB`
- `GET https://api.massive.com/v2/aggs/ticker/GENB/range/5/minute/{date}/{date}`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Markets overview](https://massive.com/quote/index.md)
- [Insider trading](https://massive.com/quote/insider-trading.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
